Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2408424 | 0.69 | ALDH1A1 (0.43) | KDM4EALDH1A1MAPTGAANPSR1 | |
| SCHEMBL1451865 | 0.68 | ALDH1A1 (0.44) | KDM4EALDH1A1MAPTGAAHDAC8 | |
| SCHEMBL7872504 | 0.62 | KCNH2 (0.33) | KDM4EALDH1A1MAPTGAAHDAC8 | |
| SCHEMBL11107461 | 0.61 | ALDH1A1 (0.52) | KDM4EALDH1A1MAPTGAANPSR1 | |
| SCHEMBL25900771 | 0.59 | ALDH1A1 (0.46) | KDM4EALDH1A1MAPTGAANPSR1 | |
| SCHEMBL16000553 | 0.59 | HDAC8 (0.46) | KDM4EALDH1A1MAPTGAANPSR1 | |
| SCHEMBL18666368 | 0.59 | ALDH1A1 (0.38) | KDM4EALDH1A1MAPTGAANPSR1 | |
| SCHEMBL1960072 | 0.58 | KMT2A (0.38) | KDM4EALDH1A1MAPTNPSR1L3MBTL1 | |
| SCHEMBL30275458 | 0.58 | KDM4E (0.39) | KDM4EALDH1A1 | |
| SCHEMBL12502917 | 0.58 | P2RX7 (0.34) | KDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050271584-A1 | Biphenyls and fluorenes as imaging agents in alzheimer's disease | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2005-12-08 | — | — | US | disclosed |
| EP-1553985-A2 | BIPHENYLS AND FLUORENES AS IMAGING AGENTS IN ALZHEIMER'S DISEASE | The Trustees of The University of Pennsylvania (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004032975-A2 | BIPHENYLS AND FLUORENES AS IMAGING AGENTS IN ALZHEIMER'S DISEASE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050271584-A1 | Biphenyls and fluorenes as imaging agents in alzheimer's disease | APP, BACE2, BACE1 | KDM4E 3436/4885ALDH1A1 1533/4885MAPT 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.